menu

contact

Italian Trulli

Tissue Selective
drug discovery

Bonito is a Boston-area biotech unlocking next generation targeted delivery. Using our small molecule and antibody discovery engines, we develop ligands that deliver payloads to any cell or tissue type. The core application is RNAi (siRNA, ASO) delivery to select tissue types with high precision and there are further applications in oncology and small molecule therapeutic discovery.

Italian Trulli
Italian Trulli
Italian Trulli
Italian Trulli
Italian Trulli

Harnessing the power of AI to generate novel delivery molecules

Unlocking Next Generation Delivery Vehicles

Bonito is a Boston-area biotech unlocking next generation targeted delivery. Using our small molecule and antibody discovery engines, we develop ligands that deliver payloads to any cell or tissue type. The core application is RNAi (siRNA, ASO) delivery to select tissue types with high precision and there are further applications in oncology and small molecule therapeutic discovery.

Italian Trulli
Italian Trulli
Italian Trulli
Italian Trulli

experience & leadership

Bonito is led by an experienced team of entrepreneurs and innovative scientists with a track record of pioneering display technologies and oligonucleotide therapeutics.

Our Leadership

Richard Wagner Ph.D.

Richard Wagner Ph.D.

CEO, Cofounder

Brant Binder

Brant Binder

President, Cofounder

Steve Shamah, Ph.D.

Steve Shamah, Ph.D.

CSO

Yun Ding, Ph.D.

Yun Ding, Ph.D.

SVP Head of Chemistry

Chris Kollmann

Chris Kollmann

VP Selection Sciences

Jim Weterings, Ph.D.

Jim Weterings, Ph.D.

VP Head of Oligo Discovery

Ribhu Nayar, Ph.D.

Ribhu Nayar, Ph.D.

Sr. Dir. Head of Biology

Dan Rosmarin

Dan Rosmarin

VP, Head of BD and Corporate Strategy

Italian Trulli

The future of targeted delivery

© Bonito Biosciences 2025